Immune response enhancement with GLS-5310 DNA primary vaccine against SARS-CoV-2 followed by administration of an mRNA vaccine heterologous boost

Heterologous boost regimens are being increasingly considered against SARS-CoV-2. We report results for the 32 of 45 participants in the Phase 1 CoV2-001 clinical trial (Kim et al., Int J Iinfect Dis 2023, 128:112–120) who elected to receive an EUA-approved SARS-CoV-2 mRNA vaccine 6 to 8 months foll...

Descripción completa

Detalles Bibliográficos
Autores principales: Kim, Woo Joo, Roberts, Christine C., Song, Joon Young, Yoon, Jin Gu, Seong, Hye, Hyun, Hak-Jun, Lee, Hyojin, Gil, Areum, Oh, Yeeun, Park, Ji-Eun, Lee, Ji-Eun, Jeon, Bohyun, Kane, Deborah, Spruill, Susan, Kudchodkar, Sagar B., Muthumani, Kar, Park, Young K., Kwon, Ijoo, Maslow, Joel N.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Author(s). Published by Elsevier Ltd. 2023
Materias:
Short Communication
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10242151/
https://www.ncbi.nlm.nih.gov/pubmed/37296017
http://dx.doi.org/10.1016/j.vaccine.2023.06.013

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10242151/
https://www.ncbi.nlm.nih.gov/pubmed/37296017
http://dx.doi.org/10.1016/j.vaccine.2023.06.013

Ejemplares similares